Rivaroxaban for kids with large heart artery aneurysms after Kawasaki disease
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Skin clinical trials.
This trial studies whether rivaroxaban (a blood thinner) can help prevent dangerous clots in children age 2 and older who have “giant” coronary artery aneurysms after Kawasaki disease. Doctors will see if it’s safe and tolerable for children who are also on standard anti-clot/anti-platelet medications for the next 3 months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re caring for a child age 2 or older
- A heart ultrasound has shown “giant” coronary artery aneurysms after the acute phase of Kawasaki disease
- Doctors recommend at least the next 3 months of blood-thinner/anti-platelet medicines to prevent clots
- The child can safely take medicine by mouth or through a feeding tube
- There is no active bleeding and no known bleeding risk that makes anticoagulant medicine unsafe
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the best dose of a blood thinner called rivaroxaban for children with a giant coronary artery aneurysm after Kawasaki disease. The goal is to prevent dangerous blood clots.
This trial is testing the drug rivaroxaban in children aged 2 to 17 who have large bulges (aneurysms) in their heart arteries after Kawasaki disease. It aims to see how the drug works in the body to prevent blood clots.
This trial tests whether a cholesterol-lowering medication called atorvastatin can help children whose hearts were damaged by Kawasaki disease (a serious childhood illness that inflames blood vessels). The study may help reduce long-term heart complications.
This study tests a blood thinner called rivaroxaban in children who have a blood clot inside the heart. The goal is to see if it safely and effectively dissolves the clot, potentially avoiding the need for stronger treatments.
This study looks at how a blood thinner called rivaroxaban is used in babies under 2 who have had a blood clot. It aims to understand safety and patterns of use to help guide treatment for young children.
This trial tests two doses of rivaroxaban (15mg and 20mg) to see how well they prevent strokes in people with non-valvular atrial fibrillation, a type of irregular heartbeat not caused by a heart valve problem. It may be an option if you need blood thinners to lower your stroke risk.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.